Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mineralys Therapeutics, Inc. - Common Stock (NQ:MLYS)

13.53 -0.47 (-3.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mineralys Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Mineralys, Sana, Aeon: These 3 Biotech Stocks Saw The Sharpest Retail Interest Spike In Q1
Three small-cap stocks have intrigued Stocktwits users the most among the biotech sector this year, thanks to promising data from clinical trials and a leadership shuffle. 
Via Stocktwits
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week
Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025. 
Via Stocktwits
Unusual volume stocks are being observed in Wednesday's session.
Which stocks have an unusual volume on Wednesday? 
Via Chartmill
Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For February 12, 2025
Via Benzinga
Insights into Mineralys Therapeutics's Upcoming Earnings
Via Benzinga
Mineralys Therapeutics Earnings Preview
Via Benzinga
Keep an eye on the top gainers and losers in Monday's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Monday's session: top gainers and losers
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate
Mineralys Therapeutics' lorundrostat met key Phase 3 and Phase 2 trial endpoints for hypertension, showing significant blood pressure reductions and a strong safety profile. 
Via Benzinga
Dow Tumbles Over 600 Points; Mineralys Therapeutics Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures US Equities
Let's uncover which stocks are experiencing notable gaps during today's session.
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Redfin, Mineralys Therapeutics, Trevi Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Which stocks are moving after the closing bell on Friday?
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Ford, Skyworks Solutions, FormFactor And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Ericsson Posts Weak Results, Joins East West Bancorp And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Why Twilio Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Scheduled For November 11, 2024
Via Benzinga
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
MLYS Investors Have Opportunity to Join Mineralys Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q2 2024
MLYS stock results show that Mineralys Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q1 2024
MLYS stock results show that Mineralys Therapeutics missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
MLYS Stock Earnings: Mineralys Therapeutics Beats EPS for Q4 2023
MLYS stock results show that Mineralys Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Arm Holdings Posts Upbeat Results, Joins Hershey, CyberArk Software, Wynn Resorts And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded mixed, with the Dow Jones gaining around 20 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.